SlideShare uma empresa Scribd logo
1 de 6
Baixar para ler offline
Boston Strategic Partners, Inc.
Business and Clinical Strategy ● Health Economics & Outcomes Research
Medical Communications ● Regulatory Strategy ● Financial Advisory
4 Wellington St. Suite 3, Boston, MA 02118 ● http://www.bostonsp.com ● realworldreports@bostonsp.com ● 617-446-3440
Real World Insights: Hospital-Treated Sepsis
July 2017
Abstract
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an
Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+
hospitals across the US, Boston Strategic Partners (BSP) estimates 30% of all hospital discharges involve treatment of infectious organisms.
Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that
hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we
conduct an in-depth analysis of Sepsis patient characteristics, medication management, costs, and laboratory testing.
Gram-positive bacteria are the likely causative agents of most Sepsis infections. Physicians treat the vast majority of these infections with
vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. From 2010-2015, drug resistant organisms caused an astonishing 40% of
bacterial Sepsis infections. After confirmatory diagnosis, over half of Sepsis patients undergo a change in antibiotic therapy.
This report provides quantitative, objective data focused on Sepsis infections requiring hospitalization captured by hospitals contributing to
Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g.
patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.
• Focused on Sepsis requiring hospitalization, detailed analysis of over 680K hospital discharges from 2009 to 2015 (including projections
through 2019)
• Epidemiology of infection in the US, including demographic information, growth, overall patient encounter attributes, and most common
causative agents
• An overview of patients with Sepsis in the US, including region, gender, and age breakdown, payer type, infection type, associated patient
comorbidities, and antibiotic usage
• Analysis of Length of Stay (LOS), mortality, total costs, and admission data and how they correlate with the following:
• Age of patient
• APACHE II score
• Care setting
• Antibiotic usage
• Examination of frequently ordered lab tests and cultures with data on turnaround time (TAT) and results
• Assessment of confirmatory diagnostic results, empiric therapy, and how results impact empiric therapy
• Treatment duration of frequently used antibiotics
• Discussion of the increasing concern regarding antibiotic-resistant organisms
• Growth
• Costs
• Outcomes
• LOS
2
Table of Contents
3
1. Outline
2. Executive Summary
3. Incidence and Impact of Disease
a. Incidence
b. Length of Stay
c. Total Cost
4. Patient Demographics
a. Age
b. Insurance type
c. Gender
d. Region
e. Mortality
f. Comorbid Conditions
5. Patient Segmentation by Diagnostic Testing
a. Causative Etiologic Agent
6. Length of Stay and Cost by Patient Segment
a. Age at Admission
b. APACHE II Score
c. First Care Setting
7. Patient Flow through the Hospital
a. Admission Site
b. Lab Testing
c. Lab TAT
d. Results
e. Etiology
f. Empiric Therapy
g. Change in treatment
8. Drug Share for Key Therapeutics
a. Most Common
b. LOS
c. APACHE Score
d. Treatment Duration
e. Product Dashboards
i. Market Share
ii. Demographics
iii. Hospitalization
9. Outcomes of Treatment
a. Antibiotic Usage
b. Mortality
c. Cost per Patient
10. Drug Resistant Sepsis
a. Current Trends
b. Costs
c. Comorbidity
d. LOS
e. Mortality
11. Database Overview
12. Methodology
Executive Summary
Methodology Overview:
Using an electronic health record (EHR) database with information collected from 614 hospitals across
the US, we evaluated overall trends in the diagnosis, treatment, costs, and outcomes associated with
acute infections requiring hospitalization (n=681,251 patients from 2010-2015). In addition, we
conducted an in-depth analysis for specific types of infections. This report will focus on the treatment
of Sepsis in the hospital.
Incidence and Impact of Disease:
In 2014, the US healthcare spending crossed $3.0 trillion with nearly 1/3 ($971 billion) spent on
hospitalizations.1 In 2013, an estimated 13.7 million hospital discharges (~30% of all hospital
discharges) involved treatment of infectious organisms.2
At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections
account for approximately $212 billion in annual spending (7% of total healthcare expenditure).
Sepsis accounts for approximately 1.15 MM inpatient stays per year, or ~12% of all hospital stays. Of
these patients, approximately 33% have confirmed bacterial agents as the cause of infection.
4
Source: CMS, 2016, HCUP, 2016, BSP EHR database
Market Share of Piperacillin-tazobactam
Piperacillin-tazobactam Dashboard
5
14.30%
Demographics Hospitalization
Median
APACHE II
Score
Gender
Breakdown
Mortality Rate
Median Length
of Stay
AWP Per Dose
Median
Number of
Doses
Duration of
Treatment per
Patient
IV
3.375 g:
$13.20 - $21.75
4.5 g:
$17.60 - $27.55
27 doses per
visit
3.3 Days
Rank*: 11th
7.0
49.0% Female
51.0% Male
11%
6.8 Days
Rank: T-9th
Source: BSP EHR database (2010 – 2015), RedBook, 2016, Sanford Guide to Antimicrobial Therapy, 2009
*Shortest duration has highest rank
1-9, 0.1% 10-19,
0.4%
20-29,
2.9%
30-39,
5.4%
40-49,
10.8%
50-59,
16.0%
60-69,
21.1%
70-79,
20.4%
80-89,
19.0%
90-99,
3.9%
100+, 0.1%
Drug
The dataset represents 10% of US hospitals and 16% of the US population
with data from over 273MM patient visits
6
Pacific
Hospitals: 43 (7%)
Visits: 23.2 MM
Patients: 4.6 MM (9%)
Mountain
Hospitals: 58 (11%)
Visits: 11.9 MM
Patients: 1.8 MM (8%)
West North Central
Hospitals: 83 (11%)
Visits: 41.5 MM
Patients: 6.5 MM (31%)
East North Central
Hospitals: 80 (9%)
Visits: 19.9 MM
Patients: 3.8 MM (8%)
West South Central
Hospitals: 58 (6%)
Visits: 15.8 MM
Patients: 3.2 MM (8%)
New England
Hospitals: 24 (10%)
Visits: 30.3 MM
Patients: 2.9 MM (19%)
Mid Atlantic
Hospitals: 95 (19%)
Visits: 84.6 MM
Patients: 16.1 MM (39%)
South Atlantic
Hospitals: 42 (5%)
Visits: 7.7 MM
Patients: 1.8 MM (3%)
East South Central
Hospitals: 110 (23%)
Visits: 37.8 MM
Patients: 8.9 MM (47%)
Dataset (% of total US market)
Overall
614 Hospitals
273 MM Patient Visits
56 MM Unique Patients
January 2000 – March 2015
Source: BSP EHR database, HCUP, US Census

Mais conteúdo relacionado

Mais procurados

Levels of Utilization and Socio - Economic Factors Influencing Adherence to U...
Levels of Utilization and Socio - Economic Factors Influencing Adherence to U...Levels of Utilization and Socio - Economic Factors Influencing Adherence to U...
Levels of Utilization and Socio - Economic Factors Influencing Adherence to U...inventionjournals
 
Determinants of first line antiretroviral treatment failure in public hospita...
Determinants of first line antiretroviral treatment failure in public hospita...Determinants of first line antiretroviral treatment failure in public hospita...
Determinants of first line antiretroviral treatment failure in public hospita...Alexander Decker
 
Retrospective Review of PONV Practice Patterns at a Large Academic Medical Ce...
Retrospective Review of PONV Practice Patterns at a Large Academic Medical Ce...Retrospective Review of PONV Practice Patterns at a Large Academic Medical Ce...
Retrospective Review of PONV Practice Patterns at a Large Academic Medical Ce...Alexis Rondon
 
Depresion y vih rep2014
Depresion y vih rep2014Depresion y vih rep2014
Depresion y vih rep2014Rosa Alcayaga
 
Preliminary study of Prescription audit for evaluation of prescribing pattern...
Preliminary study of Prescription audit for evaluation of prescribing pattern...Preliminary study of Prescription audit for evaluation of prescribing pattern...
Preliminary study of Prescription audit for evaluation of prescribing pattern...SriramNagarajan16
 
Bstat01 introduction
Bstat01 introductionBstat01 introduction
Bstat01 introductionjoebloggs1888
 
Alcohol use and crash risk study
Alcohol use and crash risk studyAlcohol use and crash risk study
Alcohol use and crash risk studyMr Christia
 
Homeopathy and antimicrobial resistance
Homeopathy and antimicrobial resistanceHomeopathy and antimicrobial resistance
Homeopathy and antimicrobial resistancehome
 
Applications of statistics in medical Research and Healthr
Applications of statistics in medical Research and HealthrApplications of statistics in medical Research and Healthr
Applications of statistics in medical Research and HealthrMuhammadNafees42
 
Adherencia al tarv en am latina y caribe
Adherencia al tarv en am latina y caribeAdherencia al tarv en am latina y caribe
Adherencia al tarv en am latina y caribeRosa Alcayaga
 
Concept of risk in pharmacoepidemiology Presentation
Concept of risk in pharmacoepidemiology PresentationConcept of risk in pharmacoepidemiology Presentation
Concept of risk in pharmacoepidemiology PresentationMdshams244
 
An open letter to all clinical pharmacists 2016 pharmaceutical care medical l...
An open letter to all clinical pharmacists 2016 pharmaceutical care medical l...An open letter to all clinical pharmacists 2016 pharmaceutical care medical l...
An open letter to all clinical pharmacists 2016 pharmaceutical care medical l...M. Luisetto Pharm.D.Spec. Pharmacology
 
Steps and impact of pharmaceutical care and clinical pharmacy development on ...
Steps and impact of pharmaceutical care and clinical pharmacy development on ...Steps and impact of pharmaceutical care and clinical pharmacy development on ...
Steps and impact of pharmaceutical care and clinical pharmacy development on ...M. Luisetto Pharm.D.Spec. Pharmacology
 
Application of bio statistics
Application of bio statisticsApplication of bio statistics
Application of bio statisticsarshilajaan
 
Biostatistics Roles and Responsibilities in Clinical Research | Pubrica
Biostatistics Roles and Responsibilities in Clinical Research | PubricaBiostatistics Roles and Responsibilities in Clinical Research | Pubrica
Biostatistics Roles and Responsibilities in Clinical Research | PubricaPubrica
 

Mais procurados (20)

Levels of Utilization and Socio - Economic Factors Influencing Adherence to U...
Levels of Utilization and Socio - Economic Factors Influencing Adherence to U...Levels of Utilization and Socio - Economic Factors Influencing Adherence to U...
Levels of Utilization and Socio - Economic Factors Influencing Adherence to U...
 
Determinants of first line antiretroviral treatment failure in public hospita...
Determinants of first line antiretroviral treatment failure in public hospita...Determinants of first line antiretroviral treatment failure in public hospita...
Determinants of first line antiretroviral treatment failure in public hospita...
 
Retrospective Review of PONV Practice Patterns at a Large Academic Medical Ce...
Retrospective Review of PONV Practice Patterns at a Large Academic Medical Ce...Retrospective Review of PONV Practice Patterns at a Large Academic Medical Ce...
Retrospective Review of PONV Practice Patterns at a Large Academic Medical Ce...
 
Depresion y vih rep2014
Depresion y vih rep2014Depresion y vih rep2014
Depresion y vih rep2014
 
Preliminary study of Prescription audit for evaluation of prescribing pattern...
Preliminary study of Prescription audit for evaluation of prescribing pattern...Preliminary study of Prescription audit for evaluation of prescribing pattern...
Preliminary study of Prescription audit for evaluation of prescribing pattern...
 
Introduction statistics
Introduction statisticsIntroduction statistics
Introduction statistics
 
Bstat01 introduction
Bstat01 introductionBstat01 introduction
Bstat01 introduction
 
Alcohol use and crash risk study
Alcohol use and crash risk studyAlcohol use and crash risk study
Alcohol use and crash risk study
 
Homeopathy and antimicrobial resistance
Homeopathy and antimicrobial resistanceHomeopathy and antimicrobial resistance
Homeopathy and antimicrobial resistance
 
Applications of statistics in medical Research and Healthr
Applications of statistics in medical Research and HealthrApplications of statistics in medical Research and Healthr
Applications of statistics in medical Research and Healthr
 
AITRP eHIT 101 tutorial
AITRP eHIT 101 tutorialAITRP eHIT 101 tutorial
AITRP eHIT 101 tutorial
 
Adherencia al tarv en am latina y caribe
Adherencia al tarv en am latina y caribeAdherencia al tarv en am latina y caribe
Adherencia al tarv en am latina y caribe
 
Concept of risk in pharmacoepidemiology Presentation
Concept of risk in pharmacoepidemiology PresentationConcept of risk in pharmacoepidemiology Presentation
Concept of risk in pharmacoepidemiology Presentation
 
An open letter to all clinical pharmacists 2016 pharmaceutical care medical l...
An open letter to all clinical pharmacists 2016 pharmaceutical care medical l...An open letter to all clinical pharmacists 2016 pharmaceutical care medical l...
An open letter to all clinical pharmacists 2016 pharmaceutical care medical l...
 
Steps and impact of pharmaceutical care and clinical pharmacy development on ...
Steps and impact of pharmaceutical care and clinical pharmacy development on ...Steps and impact of pharmaceutical care and clinical pharmacy development on ...
Steps and impact of pharmaceutical care and clinical pharmacy development on ...
 
Vaccine safety
Vaccine safetyVaccine safety
Vaccine safety
 
Application of bio statistics
Application of bio statisticsApplication of bio statistics
Application of bio statistics
 
Lancet oncol 2021
Lancet oncol 2021Lancet oncol 2021
Lancet oncol 2021
 
Pharmacoepideiology
PharmacoepideiologyPharmacoepideiology
Pharmacoepideiology
 
Biostatistics Roles and Responsibilities in Clinical Research | Pubrica
Biostatistics Roles and Responsibilities in Clinical Research | PubricaBiostatistics Roles and Responsibilities in Clinical Research | Pubrica
Biostatistics Roles and Responsibilities in Clinical Research | Pubrica
 

Semelhante a Sepsis Report - Diagnosis and Treatment

Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemTackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemViewics
 
Central Line-associated Bloodstream Infections.Walden Universi
Central Line-associated Bloodstream Infections.Walden UniversiCentral Line-associated Bloodstream Infections.Walden Universi
Central Line-associated Bloodstream Infections.Walden UniversiMaximaSheffield592
 
An Updated Literature Review Concerning The Treatment Cost Of Multidrug-Resis...
An Updated Literature Review Concerning The Treatment Cost Of Multidrug-Resis...An Updated Literature Review Concerning The Treatment Cost Of Multidrug-Resis...
An Updated Literature Review Concerning The Treatment Cost Of Multidrug-Resis...Angela Shin
 
Reducing variation in hospital admissions from the emergency department for l...
Reducing variation in hospital admissions from the emergency department for l...Reducing variation in hospital admissions from the emergency department for l...
Reducing variation in hospital admissions from the emergency department for l...John Frias Morales, DrBA, MS
 
Prevention mrsa.ppt.shirlhooper
Prevention mrsa.ppt.shirlhooperPrevention mrsa.ppt.shirlhooper
Prevention mrsa.ppt.shirlhooperShirl Hooper
 
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...IjcmsdrJournal
 
Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]Mary Beth Levin
 
Cost burdenofchronic pain
Cost burdenofchronic painCost burdenofchronic pain
Cost burdenofchronic painPaul Coelho, MD
 
Cost burden of chronic pain
Cost burden of chronic painCost burden of chronic pain
Cost burden of chronic painPaul Coelho, MD
 
The international survey on the management of allergic rhinitis by physicians...
The international survey on the management of allergic rhinitis by physicians...The international survey on the management of allergic rhinitis by physicians...
The international survey on the management of allergic rhinitis by physicians...Georgi Daskalov
 
ciclo autonomico-short paper - Witfor 2016 paper_42
ciclo autonomico-short paper - Witfor 2016 paper_42ciclo autonomico-short paper - Witfor 2016 paper_42
ciclo autonomico-short paper - Witfor 2016 paper_42.. ..
 
Webinar: Defeating Superbugs: Hospitals on the Front Lines
Webinar: Defeating Superbugs: Hospitals on the Front Lines Webinar: Defeating Superbugs: Hospitals on the Front Lines
Webinar: Defeating Superbugs: Hospitals on the Front Lines Modern Healthcare
 
Community Acquired Pneumonia
Community Acquired PneumoniaCommunity Acquired Pneumonia
Community Acquired PneumoniaBhargav Kiran
 
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno.docx
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno.docxSYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno.docx
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno.docxdeanmtaylor1545
 
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A KnoSYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Knolisandrai1k
 
REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15Zoe Mitchell
 
Oncol Lett Vol12 No6 Pg5043
Oncol Lett Vol12 No6 Pg5043Oncol Lett Vol12 No6 Pg5043
Oncol Lett Vol12 No6 Pg5043Lenka Kellermann
 
Provonost Presentation
Provonost PresentationProvonost Presentation
Provonost Presentationsggibson
 

Semelhante a Sepsis Report - Diagnosis and Treatment (20)

Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemTackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
 
Central Line-associated Bloodstream Infections.Walden Universi
Central Line-associated Bloodstream Infections.Walden UniversiCentral Line-associated Bloodstream Infections.Walden Universi
Central Line-associated Bloodstream Infections.Walden Universi
 
An Updated Literature Review Concerning The Treatment Cost Of Multidrug-Resis...
An Updated Literature Review Concerning The Treatment Cost Of Multidrug-Resis...An Updated Literature Review Concerning The Treatment Cost Of Multidrug-Resis...
An Updated Literature Review Concerning The Treatment Cost Of Multidrug-Resis...
 
Reducing variation in hospital admissions from the emergency department for l...
Reducing variation in hospital admissions from the emergency department for l...Reducing variation in hospital admissions from the emergency department for l...
Reducing variation in hospital admissions from the emergency department for l...
 
Prevention mrsa.ppt.shirlhooper
Prevention mrsa.ppt.shirlhooperPrevention mrsa.ppt.shirlhooper
Prevention mrsa.ppt.shirlhooper
 
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
Clinical Features and Patterns of CD4+ T Lymphocyte Counts Among HIV/AIDS Pat...
 
Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]
 
Cost burdenofchronic pain
Cost burdenofchronic painCost burdenofchronic pain
Cost burdenofchronic pain
 
Cost burden of chronic pain
Cost burden of chronic painCost burden of chronic pain
Cost burden of chronic pain
 
The international survey on the management of allergic rhinitis by physicians...
The international survey on the management of allergic rhinitis by physicians...The international survey on the management of allergic rhinitis by physicians...
The international survey on the management of allergic rhinitis by physicians...
 
ciclo autonomico-short paper - Witfor 2016 paper_42
ciclo autonomico-short paper - Witfor 2016 paper_42ciclo autonomico-short paper - Witfor 2016 paper_42
ciclo autonomico-short paper - Witfor 2016 paper_42
 
Webinar: Defeating Superbugs: Hospitals on the Front Lines
Webinar: Defeating Superbugs: Hospitals on the Front Lines Webinar: Defeating Superbugs: Hospitals on the Front Lines
Webinar: Defeating Superbugs: Hospitals on the Front Lines
 
Bmj.i5813.full
Bmj.i5813.fullBmj.i5813.full
Bmj.i5813.full
 
Community Acquired Pneumonia
Community Acquired PneumoniaCommunity Acquired Pneumonia
Community Acquired Pneumonia
 
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno.docx
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno.docxSYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno.docx
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno.docx
 
Hiv
HivHiv
Hiv
 
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A KnoSYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno
SYSTEMS-LEVEL QUALITY IMPROVEMENTFrom Cues to Nudge A Kno
 
REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15
 
Oncol Lett Vol12 No6 Pg5043
Oncol Lett Vol12 No6 Pg5043Oncol Lett Vol12 No6 Pg5043
Oncol Lett Vol12 No6 Pg5043
 
Provonost Presentation
Provonost PresentationProvonost Presentation
Provonost Presentation
 

Último

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 

Último (20)

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 

Sepsis Report - Diagnosis and Treatment

  • 1. Boston Strategic Partners, Inc. Business and Clinical Strategy ● Health Economics & Outcomes Research Medical Communications ● Regulatory Strategy ● Financial Advisory 4 Wellington St. Suite 3, Boston, MA 02118 ● http://www.bostonsp.com ● realworldreports@bostonsp.com ● 617-446-3440 Real World Insights: Hospital-Treated Sepsis July 2017
  • 2. Abstract In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) estimates 30% of all hospital discharges involve treatment of infectious organisms. Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of Sepsis patient characteristics, medication management, costs, and laboratory testing. Gram-positive bacteria are the likely causative agents of most Sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. From 2010-2015, drug resistant organisms caused an astonishing 40% of bacterial Sepsis infections. After confirmatory diagnosis, over half of Sepsis patients undergo a change in antibiotic therapy. This report provides quantitative, objective data focused on Sepsis infections requiring hospitalization captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship. • Focused on Sepsis requiring hospitalization, detailed analysis of over 680K hospital discharges from 2009 to 2015 (including projections through 2019) • Epidemiology of infection in the US, including demographic information, growth, overall patient encounter attributes, and most common causative agents • An overview of patients with Sepsis in the US, including region, gender, and age breakdown, payer type, infection type, associated patient comorbidities, and antibiotic usage • Analysis of Length of Stay (LOS), mortality, total costs, and admission data and how they correlate with the following: • Age of patient • APACHE II score • Care setting • Antibiotic usage • Examination of frequently ordered lab tests and cultures with data on turnaround time (TAT) and results • Assessment of confirmatory diagnostic results, empiric therapy, and how results impact empiric therapy • Treatment duration of frequently used antibiotics • Discussion of the increasing concern regarding antibiotic-resistant organisms • Growth • Costs • Outcomes • LOS 2
  • 3. Table of Contents 3 1. Outline 2. Executive Summary 3. Incidence and Impact of Disease a. Incidence b. Length of Stay c. Total Cost 4. Patient Demographics a. Age b. Insurance type c. Gender d. Region e. Mortality f. Comorbid Conditions 5. Patient Segmentation by Diagnostic Testing a. Causative Etiologic Agent 6. Length of Stay and Cost by Patient Segment a. Age at Admission b. APACHE II Score c. First Care Setting 7. Patient Flow through the Hospital a. Admission Site b. Lab Testing c. Lab TAT d. Results e. Etiology f. Empiric Therapy g. Change in treatment 8. Drug Share for Key Therapeutics a. Most Common b. LOS c. APACHE Score d. Treatment Duration e. Product Dashboards i. Market Share ii. Demographics iii. Hospitalization 9. Outcomes of Treatment a. Antibiotic Usage b. Mortality c. Cost per Patient 10. Drug Resistant Sepsis a. Current Trends b. Costs c. Comorbidity d. LOS e. Mortality 11. Database Overview 12. Methodology
  • 4. Executive Summary Methodology Overview: Using an electronic health record (EHR) database with information collected from 614 hospitals across the US, we evaluated overall trends in the diagnosis, treatment, costs, and outcomes associated with acute infections requiring hospitalization (n=681,251 patients from 2010-2015). In addition, we conducted an in-depth analysis for specific types of infections. This report will focus on the treatment of Sepsis in the hospital. Incidence and Impact of Disease: In 2014, the US healthcare spending crossed $3.0 trillion with nearly 1/3 ($971 billion) spent on hospitalizations.1 In 2013, an estimated 13.7 million hospital discharges (~30% of all hospital discharges) involved treatment of infectious organisms.2 At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for approximately $212 billion in annual spending (7% of total healthcare expenditure). Sepsis accounts for approximately 1.15 MM inpatient stays per year, or ~12% of all hospital stays. Of these patients, approximately 33% have confirmed bacterial agents as the cause of infection. 4 Source: CMS, 2016, HCUP, 2016, BSP EHR database
  • 5. Market Share of Piperacillin-tazobactam Piperacillin-tazobactam Dashboard 5 14.30% Demographics Hospitalization Median APACHE II Score Gender Breakdown Mortality Rate Median Length of Stay AWP Per Dose Median Number of Doses Duration of Treatment per Patient IV 3.375 g: $13.20 - $21.75 4.5 g: $17.60 - $27.55 27 doses per visit 3.3 Days Rank*: 11th 7.0 49.0% Female 51.0% Male 11% 6.8 Days Rank: T-9th Source: BSP EHR database (2010 – 2015), RedBook, 2016, Sanford Guide to Antimicrobial Therapy, 2009 *Shortest duration has highest rank 1-9, 0.1% 10-19, 0.4% 20-29, 2.9% 30-39, 5.4% 40-49, 10.8% 50-59, 16.0% 60-69, 21.1% 70-79, 20.4% 80-89, 19.0% 90-99, 3.9% 100+, 0.1% Drug
  • 6. The dataset represents 10% of US hospitals and 16% of the US population with data from over 273MM patient visits 6 Pacific Hospitals: 43 (7%) Visits: 23.2 MM Patients: 4.6 MM (9%) Mountain Hospitals: 58 (11%) Visits: 11.9 MM Patients: 1.8 MM (8%) West North Central Hospitals: 83 (11%) Visits: 41.5 MM Patients: 6.5 MM (31%) East North Central Hospitals: 80 (9%) Visits: 19.9 MM Patients: 3.8 MM (8%) West South Central Hospitals: 58 (6%) Visits: 15.8 MM Patients: 3.2 MM (8%) New England Hospitals: 24 (10%) Visits: 30.3 MM Patients: 2.9 MM (19%) Mid Atlantic Hospitals: 95 (19%) Visits: 84.6 MM Patients: 16.1 MM (39%) South Atlantic Hospitals: 42 (5%) Visits: 7.7 MM Patients: 1.8 MM (3%) East South Central Hospitals: 110 (23%) Visits: 37.8 MM Patients: 8.9 MM (47%) Dataset (% of total US market) Overall 614 Hospitals 273 MM Patient Visits 56 MM Unique Patients January 2000 – March 2015 Source: BSP EHR database, HCUP, US Census